A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients

Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the prostate.
2. At the time of enrollment, patients must have evidence of metastatic disease, with either measurable disease per RECIST criteria or non- measurable disease (i.e. positive bones scan) and PSA \> 5 ng/mm3.
3. Disease progression following androgen deprivation therapy.
4. Progression is defined according to the PSA Working Group criteria (see 6.1.3 and 6.3).
5. Serum testosterone levels \< 50 ng/mm3 (unless surgically castrate). Patients must continue androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.
6. No use of an antiandrogen for at least 4 weeks.
7. Have not been treated with chemotherapy before.
8. ECOG performance status of \<= 2.
9. Laboratory criteria for entry:

   * White blood cell (WBC) =\> 3000/mm3
   * Platelets =\> 100,000/mm3
   * AST \< 2.5 x upper limit of normal
   * Calculated CCT of =\> 40 ml/min
10. Signed informed consent form.
11. Age: 30 years old and above

Exclusion Criteria:

1. Significant peripheral neuropathy defined as grade 2 or higher.
2. Within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium).
3. Concomitant chemotherapy or investigational agents.